Pharming Group (NASDAQ:PHAR - Get Free Report) shares saw unusually-high trading volume on Friday . Approximately 4,528 shares traded hands during mid-day trading, an increase of 72% from the previous session's volume of 2,625 shares.The stock last traded at $9.35 and had previously closed at $9.33.
Wall Street Analyst Weigh In
Separately, HC Wainwright restated a "buy" rating and issued a $37.00 price target on shares of Pharming Group in a research report on Thursday, March 14th.
Check Out Our Latest Report on Pharming Group
Pharming Group Stock Performance
The stock has a market capitalization of $661.03 million, a price-to-earnings ratio of -71.42 and a beta of 0.16. The company has a quick ratio of 3.33, a current ratio of 4.06 and a debt-to-equity ratio of 0.62. The stock's 50-day simple moving average is $11.05 and its 200 day simple moving average is $11.51.
Pharming Group (NASDAQ:PHAR - Get Free Report) last released its quarterly earnings results on Thursday, March 14th. The company reported ($0.03) EPS for the quarter, missing analysts' consensus estimates of $0.05 by ($0.08). The firm had revenue of $81.20 million during the quarter, compared to analyst estimates of $71.83 million. Pharming Group had a negative net margin of 4.13% and a negative return on equity of 4.53%. Analysts expect that Pharming Group will post -0.02 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Pharming Group
A hedge fund recently bought a new stake in Pharming Group stock. Orion Portfolio Solutions LLC acquired a new stake in shares of Pharming Group (NASDAQ:PHAR - Free Report) in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 11,715 shares of the company's stock, valued at approximately $134,000. 0.03% of the stock is currently owned by institutional investors.
About Pharming Group
(
Get Free Report)
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's commercialized product is RUCONEST, a plasma-free rhC1INH protein replacement therapy for the treatment acute hereditary angioedema (HAE) attacks.
Further Reading
Before you consider Pharming Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharming Group wasn't on the list.
While Pharming Group currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
